Fact checked by Nick Blackmer Two new vaccines for respiratory syncytial virus (RSV) are available this year for people aged ...
GSK has received approval from Japan’s MHLW for RSV vaccine Arexvy to prevent RSV disease in adults aged over 60 years ...
GSK plc has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory ...
The European Medicines Agency (EMA) and the European Centre for Disease Control (ECDC) recommend targeting people at risk in ...
Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...
Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, that can help to protect infants through the active immunisation ...
The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect ...
GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare ...
Updated COVID-19 vaccines are being rolled out in the U.S., aimed at targeting the latest, prevalent variants of the disease.
GSK’s Arexvy receives Japanese regulatory approval for prevention of respiratory syncytial virus disease for older adults: London, UK Tuesday, September 26, 2023, 10:00 Hrs [IST ...
U.S. health officials are recommending RSV vaccinations for moms-to-be as a second option to protect newborns. The Centers ...
(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60. Arexvy is a vaccine used for the prevention of respiratory syncytial ...
